Disruption of p53 in human cancer cells alters the responses to therapeutic agents.
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
We have examined the effects of commonly used chemotherapeutic agents on human colon cancer cell lines in which the p53 pathway has been specifically disrupted by targeted homologous recombination. We found that p53 had profound effects on drug responses, and these effects varied dramatically depending on the drug. The p53-deficient cells were sensitized to the effects of DNA-damaging agents as a result of the failure to induce expression of the cyclin-dependent kinase inhibitor p21. In contrast, p53 disruption rendered cells strikingly resistant to the effects of the antimetabolite 5-fluorouracil (5-FU), the mainstay of adjuvant therapy for colorectal cancer. The effects on 5-FU sensitivity were observed both in vitro and in vivo, were independent of p21, and appeared to be the result of perturbations in RNA, rather than DNA, metabolism. These results have significant implications for future efforts to maximize therapeutic efficacy in patients with defined genetic alterations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Some conventional chemotherapeutic drugs depend on the activation of p53 for their efficacy.”
From CDK4 inhibition diminishes p53 activation by MDM2 antagonists (2018) · cites this paper as [44]
The cited source says what the claim attributes to it.
In the citing paper
“Comparing p53-proficient and -deficient HCT116 cells, such a dependency was found in particular for 5-fluorouracil (5-FU)44.”
From CDK4 inhibition diminishes p53 activation by MDM2 antagonists (2018) · cites this paper as [44]
In the citing paper
“A series of clinical studies have confirmed that CRC patients with wild-type P53 can benefit from 5-FU, and CRC patients with mutant P53 have a poor prognosis when receiving adjuvant chemotherapy [258,259,260].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [259]
In the citing paper
“A series of clinical studies have confirmed that CRC patients with wild-type P53 can benefit from 5-FU, and CRC patients with mutant P53 have a poor prognosis when receiving adjuvant chemotherapy [258,259,260].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [259]
In the citing paper
“On the other hand, the same report showed that p53-deficient cells displayed a higher sensitivity towards topoisomerase inhibitors such as Adriamycin.”
From CDK4 inhibition diminishes p53 activation by MDM2 antagonists (2018) · cites this paper as [44]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Green, D. R., & Reed, J. C. (1998) · Science · doi:10.1126/science.281.5381.1309 · Cited by 8,965
p53, the cellular gatekeeper for growth and division
Levine, A. J. (1997) · Cell · doi:10.1016/s0092-8674(00)81871-1 · Cited by 7,693
Requirement for p53 and p21 to Sustain G 2 Arrest After DNA Damage
Bunz, F., Dutriaux, A., Lengauer, C., Waldman, T., Zhou, S., Brown, J. P., Sedivy, J. M., Kinzler, K. W., & Vogelstein, B. (1998) · Science · doi:10.1126/science.282.5393.1497 · Cited by 2,803 · cited 4×
“We attribute this difference to the small amount of p53independent p21 induction following DNA damage that occurs after adriamycin treatment of p53-deficient cells (not shown), similar to that observed after γ-irradiation (14).”
BackgroundMethodInfluentialSelf-citationA model for p53-induced apoptosis
Polyak, K., Xia, Y., Zweier, J. L., Kinzler, K. W., & Vogelstein, B. (1997) · Nature · doi:10.1038/38525 · Cited by 2,500
Self-citationKo, L. J., & Prives, C. (1996) · Genes & Development · doi:10.1101/gad.10.9.1054 · Cited by 2,344 · cited 1×
“Introduction The p53 gene is inactivated in the majority of human cancers, resulting in profound effects on cell birth and death processes (1, 2).”
BackgroundMice Lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control
Deng, C., Zhang, P., Wade Harper, J., Elledge, S. J., & Leder, P. (1995) · Cell · doi:10.1016/0092-8674(95)90039-x · Cited by 2,113
p53 Status and the Efficacy of Cancer Therapy in Vivo
Lowe, S. W., Bodis, S., McClatchey, A., Remington, L., Ruley, H. E., Fisher, D. E., Housman, D. E., & Jacks, T. (1994) · Science · doi:10.1126/science.7973635 · Cited by 1,469 · cited 1×
“with mouse cells, for example, have provided unequivocal evidence of drug resistance after p53 inactivation (9, 10), but the extrapolation of these results to humans is far from straightforward.”
BackgroundApoptosis in cancer therapy: Crossing the threshold
Fisher, D. E. (1994) · Cell · doi:10.1016/0092-8674(94)90518-5 · Cited by 1,315
Is a p53-Regulated Inhibitor of G2/M Progression
Hermeking, H., Lengauer, C., Polyak, K., He, T.-C., Zhang, L., Thiagalingam, S., Kinzler, K. W., & Vogelstein, B. (1997) · Molecular Cell · doi:10.1016/s1097-2765(00)80002-7 · Cited by 1,251 · cited 1×
“The checkpoint function of p53 is mediated by the genes it transcriptionally regulates, including p21 (14, 15, 16) and 14-3-3σ (28), and keeps cells from progressing from G1 to S or G2 to M after DNA damage.”
BackgroundSelf-citationRadiation-induced cell cycle arrest compromised by p21 deficiency
Brugarolas, J., Chandrasekaran, C., Gordon, J. I., Beach, D., Jacks, T., & Hannon, G. J. (1995) · Nature · doi:10.1038/377552a0 · Cited by 1,242
Research works printed but not linked: 6
- Hawkins, 1996, Cancer Res, 56, 892
- O’Connor, 1997, Cancer Res, 57, 4285
- Waldman, 1995, Cancer Res, 55, 5187
- Geoffroy, 1994, Oncol Res, 6, 581
- Wyllie, 1997, Eur J Cell Biol, 73, 189
- Cory, 1979, Cancer Res, 39, 4905
Cited by
Items 701–800 of 1,000
Lord, R. M., Zegke, M., Henderson, I., Pask, C. M., Shepherd, H. J., & McGowan, P. C. (2018) · Chemistry - A European Journal · doi:10.1002/chem.201804901 · Cited by 20
Pöhland, T., Wagner, S., Mahyar-Roemer, M., & Roemer, K. (2006) · Anti-Cancer Drugs · doi:10.1097/01.cad.0000203387.29916.8e · Cited by 21
Experimental study of combination therapy with S-1 against pancreatic cancer
Yoshizawa, J., Takizawa, A., Takeuchi, O., Hiraku, O., Sasaki, K., Morimoto, Y., Atsuda, K., Inoue, G., Suzuki, Y., Asanuma, F., et al. (2009) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-009-0990-0 · Cited by 21
“It is known that 5-FU-induced apoptosis in cancer cells depends on the presence of wild-type p53, so mutation of p53 also inhibits apoptosis induction by 5-FU [18].”
BackgroundUdden, S. M. N., Morita‐Fujimura, Y., Satake, M., & Ikawa, S. (2013) · Cellular Signalling · doi:10.1016/j.cellsig.2013.10.005 · Cited by 19
5-Fluorouracil: identification of novel downstream mediators of tumour response.
Boyer, J. D., Maxwell, P. J., Longley, D. B., & Johnston, P. G. (2004) · PubMed · Cited by 19
Magnet, K. J., Orr, M. S., Cleveland, J. L., Galindo, C. R., Yang, H. J., Yang, C., Di, Y., Jain, P. T., & Gewirtz, D. A. (2001) · Biochemical Pharmacology · doi:10.1016/s0006-2952(01)00699-2 · Cited by 23
Huang, S. H., Qu, L., Cuddihy, A. R., Ragheb, R., Taya, Y., & Koromilas, A. E. (2003) · Oncogene · doi:10.1038/sj.onc.1206490 · Cited by 22
“This concentration of AD was previously shown to be the optimal one for HCT116 cells (Bunz et al., 1999).”
Du, Y., Rokavec, M., & Hermeking, H. (2023) · International Journal of Biological Sciences · doi:10.7150/ijbs.85724 · Cited by 19
“(F) SQLE expression in different cancer molecular subtypes (CMS) [19] and colorectal cancer intrinsic subtypes (CRIS).”
BackgroundMethodInfluentialHarnessing the p53-PUMA Axis to Overcome DNA Damage Resistance in Renal Cell Carcinoma
Zhou, X., Tolstov, Y. L., Arslan, A., Roth, W., Grüllich, C., Pahernik, S. A., Hohenfellner, M., & Duensing, S. M. (2014) · Neoplasia · doi:10.1016/j.neo.2014.09.012 · Cited by 18
“First, targeted deletion of p53 has been shown to sensitize cells to DNA strand break–induced cell death, which was mimicked by p21 deficiency, suggesting that the inability to upregulate this CDK inhibitor was responsible for enhanced apoptosis [25].”
BackgroundVynnytska‐Myronovska, B., Kurlishchuk, Y. V., Chen, O., Bobak, Y. P., Dittfeld, C., Hüther, M., Kunz‐Schughart, L. A., & Stasyk, O. V. (2016) · Experimental Cell Research · doi:10.1016/j.yexcr.2016.01.002 · Cited by 21
Implications of Circadian Rhythm Regulation by microRNAs in Colorectal Cancer
Ju, J., Wu, S., & Fesler, A. T. (2016) · Cancer translational medicine · doi:10.4103/2395-3977.177555 · Cited by 18
Chow, S.-E., Wang, J.-S., Chuang, S.-F., Chang, Y.-L., Chu, W.-K., Chen, W., & Chen, Y. (2010) · Cancer Gene Therapy · doi:10.1038/cgt.2010.44 · Cited by 18
Le, T. V. T., Seo, Y., Ryu, C. J., Lee, H. R., & Park, H. (2010) · Archives of Pharmacal Research · doi:10.1007/s12272-010-0720-5 · Cited by 18
Perioperative chemotherapy in locally advanced bladder cancer
Stadler, W. M., & Lerner, S. P. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13598-2 · Cited by 18
Cell cycle checkpoint status in human malignant mesothelioma cell lines: response to gamma radiation
Vivo, C., Boulangé-Lecomte, C., Levy, F., Leroy, K., Kirova, Y., Renier, A., Kheuang, L., Piedbois, P., Chopin, D. K., & Jaurand, M. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6600736 · Cited by 18
“For strategies involving anticancer drugs, the effect on cancer cells depends both on the nature of the drug and on the molecular status of the cancer cells, particularly p53 activity (Bunz et al, 1999).”
BackgroundAntiangiogenic Therapy and p53
Hammond, E. M., & Giaccia, A. J. (2002) · Science · doi:10.1126/science.297.5581.471a · Cited by 18
Fricke, E., Hermannstädter, C., Keller, G., Fuchs, M., Brunner, I., Busch, R. M., Höfler, H., Becker, K., & Luber, B. (2004) · Oncology · doi:10.1159/000077442 · Cited by 18
“In light of these findings, we investigated the genetic p53 background and p53 expression level of wt and mutant E-cadherin MDA-MB-435S transfectants. Investigation of exon 5–8 by DHPLC and Western blot analysis revealed that the p53 mutation status and expression level were unaffected by wt or mutant E-cadherin. The…”
BackgroundCharacterization of salvicine‐resistant lung adenocarcinoma A549/SAL cell line
Miao, Z., Tong, L., Zhang, J., Han, J., & Ding, J. (2004) · International Journal of Cancer · doi:10.1002/ijc.20026 · Cited by 18
Jane, E. P., Premkumar, D. R., & Pollack, I. F. (2007) · Cancer Letters · doi:10.1016/j.canlet.2007.06.020 · Cited by 18
“The p53 gene is inactivated in the many human cancers, resulting in profound effects on cell survival and apoptosis [32].”
BackgroundXiao, H. H., Makeyev, Y., Butler, J. T., Vikram, B., & Franklin, W. A. (2002) · Radiation Research · doi:10.1667/0033-7587(2002)158[0084:hupscw]2.0.co;2 · Cited by 18
Elfar, G. A., Aning, O. A., Ngai, T. W., Yeo, P., Chan, J. W. K., Sim, S. H., Goh, L., Ju, Y., Phua, C. Z. J., Yeo, J. Z. Z., et al. (2024) · Nucleic Acids Research · doi:10.1093/nar/gkae811 · Cited by 19
The Akt Inhibitor ISC-4 Synergizes with Cetuximab in 5-FU-Resistant Colon Cancer
Allen, J. E., Gallant, J., Dicker, D. T., Amin, S., Irby, R., Sharma, A. K., & El‐Deiry, W. S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0059380 · Cited by 17
“Several chemotherapies, including 5FU, have p53-dependent cytotoxic effects on tumor cell, and, therefore, chemotherapy-resistant disease commonly arises during disease progression due to frequent inactivation of the tumor suppressor p53 [13].”
Thamkachy, R., Kumar, R., Rajasekharan, K. N., & Sengupta, S. (2016) · Molecular Cancer · doi:10.1186/s12943-016-0505-7 · Cited by 18
“Paclitaxel (Taxol), another antimitotic drug that is widely used in clinics, also has been reported to strongly activate ERK and P-p38 in breast cancer cells and induce apoptosis in a p53 independent way [40].”
BackgroundKulkarni, Y. M., Yakisich, J. S., Azad, N., Venkatadri, R., Kaushik, V., O'Doherty, G. A., & Iyer, A. K. V. (2017) · Tumor Biology · doi:10.1177/1010428317705331 · Cited by 18
Zhu, S., Chen, Z., Wang, L., Peng, D., Belkhiri, A., Lockhart, A. C., & El-Rifai, W. M. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1716 · Cited by 17
“P53 is a double-sword protein that can induce apoptosis in response to high levels of DNA damage or DNA damage repair and cell survival in response to low and moderate levels of DNA damage (54).”
BackgroundHigh Risk α-HPV E6 Impairs Translesion Synthesis by Blocking POLη Induction
Wendel, S. O., Snow, J. A., Bastian, T., Brown, L. E., Hernandez, C., Burghardt, E., Kahn, A., Murthy, V., Neill, D., Smith, Z. C., et al. (2020) · Cancers · doi:10.3390/cancers13010028 · Cited by 17
“• HeLa S3 WT & HeLa S3 POLη [46] • HCT WT & HCT p53-/- [68]”
Allison, S. J., Cooke, D. J., Davidson, F. S., Elliott, P. I. P., Faulkner, R. A., Griffiths, H. B. S., Harper, O. J., Hussain, O. A., Owen‐Lynch, P. J., Phillips, R. M., et al. (2018) · Angewandte Chemie · doi:10.1002/ange.201805510 · Cited by 17
Ferrándiz, N., Martín-Pérez, J., Blanco, R. E., Dönertas, D., Weber, A., Eilers, M., Dotto, G. P., Delgado, M. D., & León, J. (2009) · DNA repair · doi:10.1016/j.dnarep.2008.12.001 · Cited by 20
Marabese, M., Marchini, S., Sabatino, M. A., Polato, F., Vikhanskaya, F., Marrazzo, E., Riccardi, E., Scanziani, E., & Broggini, M. (2005) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401622 · Cited by 17
Increased sensitivity of p53-deficient cells to anticancer agents due to loss of Pms2
Fedier, A., Ruefenacht, U. B., Schwarz, V. A., Haller, U., & Fink, D. A. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600599 · Cited by 17
“The results vary with the cell line under study and the experimental set-up, and thus both decreased and increased sensitivities have been observed in different model systems (Blandino et al, 1999; Bunz et al, 1999).”
ResultYu, Z., Wang, H., Zhang, L., Tang, A., Zhai, Q., Wen, J., Li, Y., & Li, P. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.06.083 · Cited by 17
Ma, W., Lin, Y., Xuan, W., Iversen, P. L., Smith, L. J., & Benchimol, S. (2011) · Oncogene · doi:10.1038/onc.2011.300 · Cited by 19
“In some experimental models, p53-deficiency is associated with resistance to DNA damaging agents, whereas in other models, p53-deficiency leads to enhanced drug sensitivity (Lowe et al., 1993a, b; O’Connor et al., 1997; Bunz et al., 1999; McGill and Fisher, 1999; El-Deiry, 2003).”
BackgroundThe role of p53 in death of IL-3-dependent cells in response to cytotoxic drugs
Palacios, C., del Arroyo, A. G., Silva, A., & Collins, M. K. (2000) · Oncogene · doi:10.1038/sj.onc.1203683 · Cited by 17
“From our results we can conclude that the ability of cytotoxic drugs to increase the level of p53 does not control their ability to induce p53-dependent loss of clonigenicity, in agreement with previous observations (Bunz et al., 1999).”
ResultBenzo[a]pyrene-mediated toxicity in primary pig bladder epithelial cells: A proteomic approach
Verma, N., Pink, M., Rettenmeier, A. W., & Schmitz‐Spanke, S. (2013) · Journal of Proteomics · doi:10.1016/j.jprot.2013.04.016 · Cited by 18
Motamedi, Z., Amini, S. A., Raeisi, E., LEMOIGNE, Y., & Heidarian, E. (2019) · Turkish Journal of Pharmaceutical Sciences · doi:10.4274/tjps.galenos.2019.69335 · Cited by 17
The REGγ inhibitor NIP30 increases sensitivity to chemotherapy in p53-deficient tumor cells
Gao, X. C., Wang, Q., Wang, Y., Liu, J., Liu, S., Liu, J., Zhou, X., Zhou, L., Chen, H., Pan, L., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17667-7 · Cited by 20
Key genes and drug delivery systems to improve the efficiency of chemotherapy
Torres‐Martínez, Z., Delgado, Y., Ferrer‐Acosta, Y., Suárez-Arroyo, I. J., Joaquín-Ovalle, F. M., Delinois, L. J., & Griebenow, K. H. (2020) · Cancer Drug Resistance · doi:10.20517/cdr.2020.64 · Cited by 18
“An invitro study reported that when p53 is mutated on cancer cells, anticancer drug 5-fluorouracil sensitivity is reduced[103].”
BackgroundDart, D. A., Picksley, S. M., Cooper, P. A., Double, J. A., & Bibby, M. C. (2004) · International Journal of Oncology · doi:10.3892/ijo.24.1.115 · Cited by 16
“Mouse testicular carcinoma (18) Mouse adenocarcinoma of the colon (19) Mouse adenocarcinoma of the colon (19) Ascites cells of MAC15 (20) Mouse adenocarcinoma of the colon (21) Mouse adenocarcinoma of the colon (21) Mouse adenocarcinoma of the colon (21) Mouse adenocarcinoma of the colon (22) Mouse adenocarcinoma of t…”
BackgroundMolecular mechanisms of cellular senescence and immortalization of human cells
Kiyono, T. (2007) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.11.12.1623 · Cited by 19
“It has been suggested that p21 plays a critical role in both inducing p53-dependent senescence and protecting against apoptosis [12-15] .”
BackgroundRASSF1A expression inhibits the growth of hepatocellular carcinoma from Qidong County
Xue, W., Li, C., Zhou, X., Guan, H.-G., Qin, L., Li, P., Wang, Z., & Qian, H. (2007) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2007.05067.x · Cited by 16
Saini, K. S., Hamidullah, Ashraf, R., Mandalapu, D., Das, S., Siddiqui, M. Q., Dwivedi, S., Sarkar, J., Sharma, V. L., & Konwar, R. (2016) · Molecular Carcinogenesis · doi:10.1002/mc.22588 · Cited by 16
“As a guardian of genome, p53 confers anti-cancer effect in response to stress and DNA damage and drive abnormal cancer cells toward cell death [54].”
BackgroundHarakeh, S., Diab-Assef, M., El-Sabban, M. E., Haddadin, M. J., & Gali‐Muhtasib, H. U. (2004) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2004.05.002 · Cited by 17
“The upregulation is thought to take place through a post-transcriptional mechanism that stabilizes the protein itself [44–46].”
BackgroundRetractedSenescence: a companion in chemotherapy?
Berns, A. J. M. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00063-6 · Cited by 19
Michienzi, S., Bucci, B., Falzacappa, C. V., Patriarca, V., Stigliano, A., Panacchia, L., Brunetti, E., Toscano, V., & Misiti, S. (2007) · Journal of Endocrinology · doi:10.1677/joe.1.07065 · Cited by 22
“…though we already knew that expression of wt-p53 was required for 5-FU-induced apoptosis and to potentiate the 5-FU-cytotoxicity (Lowe et al. 1993, Bunz et al. 1999, Eisold et al. 2004), we decided to verify if the combination 5-FU and T3 could inhibit the tumor proliferation in a p53-independent…”
BackgroundTime series analysis of TP53 gene mutations in recurrent HPV-negative vulvar squamous cell carcinoma
Regauer, S., Kashofer, K., & Reich, O. (2018) · Modern Pathology · doi:10.1038/s41379-018-0141-4 · Cited by 15
An Integrated Analysis of the Response of Colorectal Adenocarcinoma Caco-2 Cells to X-Ray Exposure
Guardamagna, I., Lonati, L., Savio, M., Stivala, L. A., Ottolenghi, A., & Baiocco, G. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.688919 · Cited by 19
“However, particularly in comparison to other colorectal cancer cell lines, Caco-2 exhibit peculiar features, among which: their poorly aggressive tumor phenotype allow studying mechanisms at play at an early stage of cancer progression, also using radiation as a probe to gain molecular understanding; their p53 status…”
BackgroundAvallone, A., Gennaro, E. D., Bruzzese, F., Laus, G., Delrio, P., Caraglia, M., Pepe, S., Comella, P., & Budillon, A. (2007) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e32809ef9b7 · Cited by 15
Bychkov, M. L., Gasparian, M. E., Dolgikh, D. A., & Kirpichnikov, M. P. (2014) · PLoS ONE · doi:10.1371/journal.pone.0109756 · Cited by 15
“HCT116 p532/2 were kindly provided by Prof. B. Vogelstein (Johns Hopkins University School of Medicine) [27].”
BackgroundCasado, J., Iñigo-Chaves, A., Jiménez-Ruiz, S. M., Ríos‐Arrabal, S., Carazo, Á., González‐Puga, C., Núñez, M. I., Ruiz‐Extremera, A., Salmerón, J., & León, J. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18061251 · Cited by 18
“The presence of p53 mutations induces resistance in cultured CRC cells and is indicative of poor survival in patients after 5-fluorouracil treatment [52,53], the gold standard in CRC chemotherapy treatment that, depending on the tumor stage, is combined with other drugs [54].”
Tonnessen-Murray, C. A., Ungerleider, N., Rao, S. G., Wasylishen, A. R., Frey, W. D., & Jackson, J. G. (2018) · Translational Oncology · doi:10.1016/j.tranon.2018.05.003 · Cited by 15
CDX2 does not suppress tumorigenicity in the human gastric cancer cell line MKN45
Dang, L. H., Chen, F., Knock, S. A., Huang, E. H., Feng, J., Appelman, H. D., & Dang, D. T. (2005) · Oncogene · doi:10.1038/sj.onc.1209243 · Cited by 16
“This investigative approach has provided important insights into the functions of genes relevant to colon cancer such as K-ras, p53, p21, and b-catenin (Shirasawa et al., 1993; Waldman et al., 1995; Brown et al., 1997; Bunz et al., 1998, 1999; Chan et al., 1999, 2002; Kim et al., 2002, 2004).”
Shiratori, Y., Sakaguchi, K., Shiraha, H., Hiraoka, S., Harada, K., Horii, J., Kato, J., & Fujita, H. (2007) · Oncology Reports · doi:10.3892/or.18.5.1129 · Cited by 15
Wagner, S., & Roemer, K. (2005) · Biochemical Pharmacology · doi:10.1016/j.bcp.2004.12.017 · Cited by 17
Overexpression of p73 enhances cisplatin-induced apoptosis in HeLa cells
Kim, K., Jung, C.-S., & Choi, K. (2006) · Archives of Pharmacal Research · doi:10.1007/bf02974277 · Cited by 15
“Moreover, it has been reported that p53 is important in the response of human colorectal tumor cells to different chemotherapeutic agents, which further suggests that the combination of p53 and cisplatin could be a very promising new therapy (Bunz et al., 1999).”
Backgroundp53 as an Effector or Inhibitor of Therapy Response
Ablain, J., Poirot, B., Esnault, C., Lehmann-Che, J., & de Thé, H. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026260 · Cited by 15
Nguyen, N. T. H., Sennoune, S. R., Dharmalingam-Nandagopal, G., Sivaprakasam, S., Bhutia, Y. D., & Ganapathy, V. (2024) · Cells · doi:10.3390/cells13110951 · Cited by 18
“…that Our recent studies with breast cancer cell lines have demonstrated that niclosamide causes intracellular acidification and also inhibits SLC38A5, both leading to the suppression of macropinocytosis [31]. in breast cancer cell lines, consequently leading to the induction of ferroptosis [30].”
BackgroundMethodKim, H., Kim, H.-I., Jang, E., Eom, Y. W., Yoon, G., Choi, K. S., & Kim, E. H. (2025) · Cell Death Discovery · doi:10.1038/s41420-025-02416-w · Cited by 17
“To assess whether p21 ’ s role is conserved across DNA-damaging agents, we treated cells with low-dose (5 μ M) and high-dose (50 μ M) etoposide.”
Wt p53 impairs response to chemotherapy: make lemonade to spare normal cells
Blagosklonny, M. V. (2012) · Oncotarget · doi:10.18632/oncotarget.548 · Cited by 14
“These effects varied dramatically depending on the drug and cell line [91].”
BackgroundKadioglu, O., Saeed, M. E. M., Mahmoud, N., Azawi, S. S. H., Mrasek, K., Liehr, T., & Efferth, T. (2021) · Archives of Toxicology · doi:10.1007/s00204-021-02979-4 · Cited by 14
TRIM29 Reverses Oxaliplatin Resistance of P53 Mutant Colon Cancer Cell
Lei, G., Liu, S., Yang, X. L., & He, C. (2021) · Canadian Journal of Gastroenterology and Hepatology · doi:10.1155/2021/8870907 · Cited by 18
“Clinical studies also suggest that mutant P53 increases the resistance of colorectal cancer patients to chemotherapy [15, 18, 19].”
Mara, A., Carrasco, E., Ramrez, A., Jimnez, G., López‐Ruiz, E., Pern, M., Picon‐Ruiz, M., Campos, J., Boulaiz, H., & Antonio, J. (2012) · InTech eBooks · doi:10.5772/48267 · Cited by 17
“P53 was the first target described for 5-FU- induced apoptosis, however, although several reports have demonstrated that 5-FU-induced apoptosis is dependent on the tumour suppressor p53 protein, apoptosis can also occur in mutant p53 cell lines [44,45,46,47].”
BackgroundIshida, K., Nishizuka, S., Chiba, T., Ikeda, M., Kume, K., Endo, F., Katagiri, H., Matsuo, T., Noda, H., Iwaya, T., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0043236 · Cited by 14
“We also screened p53, Tymidine Synthetase, and MDR-1 expression in pooled stomach and colon samples because it has been suggested that these proteins or encoding genes may be associated with 5-FU drug potency [18,19,20,21].”
MethodFraser, J. A., Worrall, E. G., Lin, Y., Landré, V., Pettersson, S., Blackburn, E. A., Walkinshaw, M. D., Müller, P., Vojtesek, B., Ball, K. L., et al. (2014) · Journal of Molecular Biology · doi:10.1016/j.jmb.2014.12.011 · Cited by 15
“We also evaluated whether this density-dependent phosphorylation could be observed in another cell line; we used HCT116 since this cell line is well characterized with respect to wt-p53 regulation and function [43].”
MethodEfficacy and safety of FdUMP[10] in treatment of HT-29 human colon cancer xenografts
Liu, C., Willingham, M. C., Liu, J., & Gmeiner, W. H. (2002) · International Journal of Oncology · doi:10.3892/ijo.21.2.303 · Cited by 14
Anusha, C., Sundararaju, K., Chidambaram, R. K., Rajasekaran, S., Jayaraj, J. M., Muthusamy, K., & Ravikumar, V. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26333 · Cited by 15
“As a cell cycle inhibitor, p21 has been assigned a major role in the growth arrest after DNA damage and is thought to be a key mediator of p53 tumor suppressor function (Bunz et al., 1999; Xiong et al., 1991).”
BackgroundMethylation of WTH3, a possible drug resistant gene, inhibits p53 regulated expression
Tian, K., Wang, Y., Huang, Y. S., Sun, B., Li, Y., & Xu, H. (2008) · BMC Cancer · doi:10.1186/1471-2407-8-327 · Cited by 14
P-TEFb inhibitors interfere with activation of p53 by DNA-damaging agents
Radhakrishnan, S. K., Bhat, U. G., Halasi, M., & Gartel, A. L. (2007) · Oncogene · doi:10.1038/sj.onc.1210737 · Cited by 14
“In addition, ARC inhibited Doxinduced p53-dependent (Bunz et al., 1999) activation of p21 (Figure 1c).”
BackgroundClinical significance of prognostic and predictive markers in colorectal cancer
Longley, D. B., McDermott, U., & Johnston, P. G. (2002) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500124 · Cited by 14
Hawes, D., Liu, P., Muggia, F. M., Wilczynski, S. P., Cote, R., Felix, J., Terada, K. Y., Belt, R. J., & Alberts, D. S. (2002) · Gynecologic Oncology · doi:10.1006/gyno.2002.6755 · Cited by 14
“Of particular interest with regard to the agents used in the current study is the need for a functional p53 for optimal cytotoxic actions of fluoropyrimidine inhibitors of thymidylate synthase [25–28].”
BackgroundIs There a Role for Routine p53 Testing in Colorectal Cancer?
Hoff, P. M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.021 · Cited by 14
Changes in allelic imbalances in locally advanced breast cancers after chemotherapy
Varna, M., Soliman, H. R., Feugeas, J., Turpin, E., Chapelin, D., Legrès, L., Plassa, L.-F., de Roquancourt, A., Espié, M., Misset, J. L., et al. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603937 · Cited by 13
“TP53 is known to control genomic integrity (Vogelstein et al, 2000), and is induced by cytotoxic drugs (Lowe et al, 1993; Bunz et al, 1999), whereas its potential role as a prognostic and a predictive marker in cancer patients remains controversial (Vousden and Prives, 2005; Berns, 2006).”
BackgroundBabinčák, M., Jendželovský, R., Košuth, J., Majerník, M., Vargová, J., Mikulášek, K., Zdráhal, Z., & Fedoročko, P. (2021) · Cancers · doi:10.3390/cancers13071646 · Cited by 15
“It is known that p53 knocked-out cells are more sensitive to treatment leading to DNA damage [53].”
BackgroundPostiglione, I., Barra, F., Aloj, S. M., & Palumbo, G. A. (2016) · Cell Proliferation · doi:10.1111/cpr.12274 · Cited by 16
Nakamura, K., Arai, D., & Fukuchi, K. (2004) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2004.07.032 · Cited by 13
Arnould, S., Spanswick, V. J., Macpherson, J. S., Hartley, J. A., Thurston, D. E., Jodrell, D. I., & Guichard, S. M. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0018 · Cited by 14
“Following the generation of cell stress, particularly DNA damage, p53 is posttranslationally stabilized and this is associated with increased levels of its target gene p21 (34).”
BackgroundWarusavitarne, J. H., Ramanathan, P., Kaufman, A., Robinson, B. G., & Schnitzler, M. (2006) · International Journal of Colorectal Disease · doi:10.1007/s00384-005-0071-8 · Cited by 13
“Loss of p53 function can reduce cellular sensitivity to 5FU [26, 27].”
BackgroundAllen, W. L., Jithesh, P. V., Oliver, G. R., Proutski, I., Longley, D. B., Lenz, H., Proutski, V., Harkin, P. D., & Johnston, P. G. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-687 · Cited by 13
“A number of predictive markers of response to these therapies have been proposed, however, the results are controversial [3-16] and to date, outside of KRAS testing, no predictive markers have made the transition to routine clinical use.”
ResultPoudyal, D., Cui, X., Le, P. M., Davis, T., Hofseth, A. B., Yu, J. H., Chumanevich, A. A., Wargovich, M. J., Nagarkatti, M., Nagarkatti, P. S., et al. (2012) · BioMed Research International · doi:10.1155/2012/785739 · Cited by 13
“For example, loss of p53 function can cause resistance to 5-fluorouracil (5-FU), but increased sensitivity to DNA damaging agent such as Adriamycin [18].”
BackgroundLi, Q., Zhao, L., Zheng, Z., Yang, H., Santiago, A., & Liao, D. (2011) · Journal of Virology · doi:10.1128/jvi.00492-11 · Cited by 13
“To test this, HCT116 cells and their isogenic counterpart HCT116p53 / cells, in which both alleles of the p53 gene were inactivated through homologous recombination (7), in the absence or presence of Ad12 E1B-55K expression, were left untreated or exposed to 0.”
BackgroundThe Interaction between Two Radiosensitizers: 5-Iododeoxyuridine and Caffeine
Seo, Y., Yan, T., Schupp, J. E., Yamane, K., Radivoyevitch, T., & Kinsella, T. J. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2766 · Cited by 13
“The two pairs of human colon cancer cell lines used were HCT116 versus HCT116 p53 / cells (24) and RKO versus”
MethodRepurposing of idebenone as a potential anti-cancer agent
Damiani, E., Yuecel, R., & WALLACE, H. M. (2019) · Biochemical Journal · doi:10.1042/bcj20180384 · Cited by 13
Chakrabarti, A., Gupta, K., Sharma, J. P., Yang, J., Agarwal, A., Glick, A., Zhang, Y., Agarwal, M. L., Agarwal, M. K., & Wald, D. N. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.312801 · Cited by 12
Self-citationNatural products as a means of overcoming cisplatin chemoresistance in bladder cancer
Rajendran, G., Taylor, J. A., & Woolbrigh, B. L. (2021) · Cancer Drug Resistance · doi:10.20517/cdr.2020.69 · Cited by 18
“in BCa, interacts with cisplatin in BCa, remains critical([23]).”
BackgroundWild Type p53 Transcriptionally Represses the SALL2 Transcription Factor under Genotoxic Stress
Farkas, C., Martins, C. P., Escobar, D., Hepp, M. I., Donner, D. B., Castro, A. F., Evan, G. I., Gutiérrez, J. L., Warren, R. S., & Pincheira, R. (2013) · PLoS ONE · doi:10.1371/journal.pone.0073817 · Cited by 12
“P53 wild type and p53 mutant plasmids were kindly provided by Dr. Bert Vogelstein (Johns Hopkins Medicine, U.S.”
MethodInfluentialAit-Tihyaty, M., Rachid, Z., Larroque‐Lombard, A., & Jean‐Claude, B. J. (2013) · Investigational New Drugs · doi:10.1007/s10637-013-0008-y · Cited by 13
Li (2010) · Oncology Reports · doi:10.3892/or_00001025 · Cited by 12
Skwarska, A., Ramachandran, S., Dobrynin, G., Leszczyńska, K. B., & Hammond, E. M. (2017) · Oncotarget · doi:10.18632/oncotarget.16102 · Cited by 12
“Upon combination of radiation with C-1311, the SF2 fraction dropped from 48.04% ± 2.9 to 26.64% ± 5.4 for HCT116p53−/− (Figure 6C), and from 49.62% ± 1.3 to 25.82% ± 1.9 for FLO1 cells (Figure 6D).”
MethodInfluentialSabatino, M. A., Previdi, S., & Broggini, M. (2006) · International Journal of Cancer · doi:10.1002/ijc.22362 · Cited by 12
“already been used to study the effects of the disruption of p53 on the response to therapeutic agents, including DX.(32) In these cells in vitro, DX raised the levels of p53 and subsequently of p21, which is”
MethodInfluentialMethods for screening tumors for p53 status and therapeutic exploitation
Tullo, A., D’Erchia, A. M., & Sbisà, E. (2003) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.3.3.289 · Cited by 12
PUMA Kills Stem Cells to Stall Cancer?
Yu, J. (2009) · Molecular and Cellular Pharmacology · doi:10.4255/mcpharmacol.09.14 · Cited by 13
“The HCT 116 and its isogenic p53 knockout (p53 KO) cells have been previously described (8).”
Antimetabolite incorporation into DNA: Structural and thermodynamic basis for anticancer activity
Gmeiner, W. H. (2002) · Biopolymers · doi:10.1002/bip.10214 · Cited by 12
Muñoz‐Pinedo, C., Oliver, F. J., & López‐Rivas, A. (2000) · Biochemical Journal · doi:10.1042/0264-6021:3530101 · Cited by 12
Pavelić, S. K., Marjanović, M., Poznić, M., & Kralj, M. (2009) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-009-0621-5 · Cited by 12
“Still, while the majority of the data support a role for mutated p53 in reducing chemosensitvity, the other indicate either no correlation or even increased sensitivity to chemotherapeutic agents ( Bunz et al. 1999 ).”
BackgroundBerge, G., Costea, D. E., Berg, M., Rasmussen, H., Grotterød, I., Lothe, R. A., Mælandsmo, G. M., & Flatmark, K. (2010) · Amino Acids · doi:10.1007/s00726-010-0514-6 · Cited by 12
Microsatellite Instability And Allelic Imbalance In Primary And Secondary Colorectal Cancer
Schneider, A., Rohr, S., Kelly, M. D., Mitry, R. R., Pignatelli, M., Doré, C. J., Gaub, M., Jaeck, D., Meyer, C., Oudet, P., et al. (2000) · Australian and New Zealand Journal of Surgery · doi:10.1046/j.1440-1622.2000.01904.x · Cited by 12
Kaşıkcı, E., Aydemir, E., Yoğurtçu, B. M., Şahin, F., & Bayrak, Ö. F. (2020) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520620666200508085439 · Cited by 11
P-TEFb promotes cell survival upon p53 activation by suppressing intrinsic apoptosis pathway
Wang, Z., Mačáková, M., Bugai, A., Kuznetsov, S. G., Hassinen, A., Lenasi, T., Potdar, S., Friedel, C. C., & Barborič, M. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkad001 · Cited by 11
Liu, Z., Zhao, L., Liu, Y.-W., Li, T., Fan, D., & Chen, J. J. (2007) · Journal of Molecular Biology · doi:10.1016/j.jmb.2007.09.031 · Cited by 11
“Although inactivation of the p53 pathway is believed to be responsible for a reduction of apoptosis in cancers, some p53deficient cells, including human keratinocytes expressing HPV E6, are more sensitive to certain DNA-damaging and chemotherapeutic agents (18; 19; 20; 21).”
BackgroundIntegrative biology — a strategy for systems biomedicine
Liu, E. T. (2008) · Nature Reviews Genetics · doi:10.1038/nrg2488 · Cited by 13
RECQ1 expression is upregulated in response to DNA damage and in a p53-dependent manner
Parvathaneni, S., Lu, X., Chaudhary, R., Lal, A., Madhusudan, S., & Sharma, S. (2017) · Oncotarget · doi:10.18632/oncotarget.18237 · Cited by 11
“As reported previously [43], p53KO-HCT116 cells were more sensitive to MMS treatment than p53WTHCT116 cells.”
Background
Metadata
- Authors
- Bunz, F., Hwang, P. M., Torrance, C., Waldman, T., Zhang, Y., Dillehay, L., Williams, J., Lengauer, C., Kinzler, K. W., & Vogelstein, B.
- Affiliations
- Howard Hughes Medical Institute (US)
- Georgetown University (US)
- Johns Hopkins University (US)
- Corresponding author
- Vogelstein, Bert
- Venue
- Journal of Clinical Investigation
- Published
- 1999-08-01
- Volume
- 104
- Issue
- 3
- Pages
- 263-269
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC408422
- OpenAlex
- W1982097971
- Cited by
- 1,044
- References
- 33
- Citations by year
- 2026: 10 · 2025: 14 · 2024: 17 · 2023: 26 · 2022: 23 · 2021: 19 · 2020: 27 · 2019: 26 · 2018: 25 · 2017: 24 · 2016: 36 · 2015: 32 · 2014: 35 · 2013: 43 · 2012: 38
- FWCI
- 22.48
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Foundation for Cancer Research
- Johns Hopkins University
- National Institutes of Health
- National Cancer Institute (CA 57345, R01CA057345, P50CA062924, R37CA057345, CA 62924)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Keywords
- p53, p53 deficiency, chemoresistance, 5-fluorouracil, antimetabolite resistance, p21, cyclin-dependent kinase inhibitors, DNA-damaging agents, chemosensitization, colon cancer, colorectal cancer, RNA metabolism, drug response
- MeSH terms
- Animals, Antineoplastic Agents, Colonic Neoplasms, DNA Damage, Doxorubicin, Fluorouracil, Humans, Mice, Nude, Neoplasm Transplantation, Transplantation, Heterologous, Tumor Cells, Cultured, Genes, p53, Tumor Suppressor Protein p53, Cyclins, Apoptosis, Gene Deletion, Drug Resistance, Neoplasm, Cyclin-Dependent Kinase Inhibitor p21, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.